Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
microbial transplant therapy
- Development stage
- Phase 1
- Lead developer
- Intermountain Health
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Microbial Transplant Therapy (MTT) is an investigational biologic therapy being evaluated by Dr. Joshua Stern at Intermountain Healthcare for the treatment of recurrent kidney stones. It is administered as oral capsules containing a whole community of gut microbiota derived from fecal material. The therapy is designed to modify the gut microbiome's composition, which in turn alters urinary chemistry parameters like calcium and oxalate. This modulation of intestinal metabolism is intended to reduce the risk factors for the formation of calcium-oxalate kidney stones. An early Phase 1 clinical trial (NCT05516472) is assessing the therapy's impact on urine parameters in patients with hypercalciuria and hyperoxaluria who have a history of producing at least 50% calcium-oxalate stones.
- Other names
- fecal microbiota transplant
Beyond the preview
Go deeper on microbial transplant therapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on microbial transplant therapy.